Navigation Links
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
Date:8/14/2014

areholders.

Net loss applicable to common stockholders for the six months ended June 30, 2014 was $7.3 million compared to a net loss applicable to common stockholders of $22.3 million for the comparable period in 2013. The decrease in net loss applicable to common stockholders of $15.0 million was primarily attributable to the aforementioned decrease in net loss as compared to prior year and a decrease of $2.9 million in the fair value of dividends paid in additional preferred stock to the Company's preferred shareholders.

Research and Development ExpensesResearch and development expenses for the three months ended June 30, 2014 were $1.2 million, compared to $1.2 million for the three months ended June 30, 2013 and were consistent year over year.

Research and development expenses for the six months ended June 30, 2014 were $2.7 million, compared to $15.0 million for the six months ended June 30, 2013. The decrease of $12.3 million is primarily related to the one-time charge in the first quarter of 2013 related to the fair value of common shares issued to OPKO for the purchase of substantially all of OPKO's RNAi-related assets.

General and Administrative ExpensesGeneral and administrative expenses for the three months ended June 30, 2014 were $0.9 million, compared to $1.0 million for the three months ended June 30, 2013. The decrease of $0.1 million was due was primarily due to a decrease in printing fees related to our public filings and a decrease in legal fees in connection with the Company's reverse split which was completed in July 2013.

General and administrative expenses for the six months ended June 30, 2014 were $1.7 million, compared to $1.7 million for the six months ended June 30, 2013. General and administrative expenses were consistent year over year.

Preferred Stock DividendsPreferred stock dividends were $1.2 million for the three months ended June 30, 2014, compared to $2.4 million for
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- In the farthest reaches of the Amazon rainforest, the ... together in a quest to save their ancestral knowledge ... May in a remote village on the frontier divide ... over two years work and culminated in the production ... an Amazonian tribe. The 500-page repository details medicinal plants ...
(Date:7/7/2015)... July 7, 2015   Moleculera Labs ... matching grant from the Oklahoma Center for the ... supports the development and clinical validation of new ... neuronal antigens in patients experiencing neuropsychiatric disorders such ... are intended to assist physicians in identifying the ...
(Date:7/7/2015)... ... July 07, 2015 , ... Since its inception in 2004 ... began as a conference for European Statistical Programmers, has evolved in the past ... area. Statistical Programmers, Data Managers and Biostatisticians all over the world, share, contribute ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia Alliance, ... innovation in life science R&D, has attracted a number of new members from ... ten pharmaceutical company joining as a Core member, and DNAnexus and Tessella as ...
Breaking Biology Technology:Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 2Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 3Amazonian Tribe Creates First Encyclopedia of Indigenous Medicine 4Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3PhUSE Delighted to Welcome Member Number 5.000 2Pistoia Alliance Continues to Attract New Members 2
... Amnis Corporation and Gene Company, Ltd.,announced today ... Company,will sell and service the Amnis ImageStream(R) system ... Hong Kong, Shanghai,Beijing and Guangzhou now have access ... extremely pleased to have begun what we expect ...
... and Company) (NYSE: BDX ), a global medical technology company,announced ... Bank of America 2008 Healthcare Conference ... Bernstein 24th Annual Strategic Decisions Conference 2008 ... A live webcast of BD,s presentations can be accessed from the ...
... May 7 /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that ... Glover,as a new director. Glover is the seventh ... appointed for a term expiring at the annual ... is Senior Vice President, Operations and Chief Financial ...
Cached Biology Technology:Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China 2James T. Glover Appointed to Board of Directors of Varian, Inc. 2
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... in behaviour among the population have accelerated the recent decline ... in Science shows how there has been an almost 50 ... researchers attribute to people delaying when they first have sex ... fell most steeply at young ages, with a drop in ...
... one of the oldest healing remedies known to medicine, ... A review article in the most recent issue of ... the data. , Scientists performed 22 trials involving 2,062 ... 16 trials that were performed on experimental animals. Honey ...
... created in this cool movie , ,Scientists ... created polymer nanotubes that are unusually long (about 1 centimeter) ... Described in a new paper in Proceedings of the National ... as channels for tiny volumes of chemicals in nanofluidic reactor ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Stable polymer nanotubes may have a biotech future 2
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: